Final answer:
In the EMPA-RED trial, the secondary endpoint that was assessed was the effect of Empagliflozin on kidney function in patients with type 2 diabetes and high cardiovascular risk. The assessment of kidney function as a secondary endpoint was important in understanding the overall benefits of the medication.
Step-by-step explanation:
In the EMPA-RED trial, the secondary endpoint that was assessed was the effect of Empagliflozin on kidney function in patients with type 2 diabetes and high cardiovascular risk. The trial evaluated the efficacy and safety of Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, on various outcomes including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke as primary endpoints. The assessment of kidney function as a secondary endpoint was important in understanding the overall benefits of the medication.
secondary endpoint that was assessed was the effect of Empagliflozin on kidney function in patients with type 2 diabetes and high cardiovascular risk. The trial evaluated the efficacy and safety of Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, on various outcomes including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke as primary endpoints. The assessment of kidney function as a secondary endpoint was important in understanding the overall benefits of the medication.